Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | FIGHT-202: pemigatinib in CCA

Ghassan Abou-Alfa • 2 Jun 2021
ASCO 2021
Bile Duct Cancer Gastrointestinal Cancer
FIGHT-202

Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the updated results from the FIGHT-202 trial (NCT02924376): a Phase II trial investigating the efficacy and safety of the FGFR inhibitor pemigatinib in patients with cholangiocarcinoma (CCA) and FGFR2 fusion. Pemigatinib improved patient outcomes; the overall response rate (ORR) of patients was 37% and the median overall survival (mOS) of responders was 30.1 months, compared to 13.7 months for non-responders. Adverse events were tolerable. The FIGHT-202 trial has led to the approval of pemigatinib for the treatment of CCA in patients with FGFR2 fusion by the FDA. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Ghassan Abou-Alfa

2:19
Should HCC be treated with locoregional or systemic therapies?
Ghassan Abou-Alfa • 22 Jun 2023
2:32
The role of systemic treatment in early-stage hepatocellular carcinoma
Ghassan Abou-Alfa • 22 Jun 2023
1:53
SCG101: a novel T-cell therapy in advanced hepatitis B-related HCC
Ghassan Abou-Alfa • 22 Jun 2023
3:52
What role does TIGIT inhibition have in treating hepatocellular carcinoma?
Ghassan Abou-Alfa • 22 Jun 2023

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals